I agree that this site is using cookies. You can find further informations
here
.
X
Login
My folder (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
Show Desktop-Version
Toggle navigation
Durm, Greg
12
results:
Search for persons
X
Format
Online (12)
Mediatypes
Articles (Online) (8)
OpenAccess-fulltext (4)
Sorted by: Relevance
Sorted by: Year
?
1
Analysis of Circulating Tumor DNA Predicts Outcomes of Shor..:
Jun, Soyeong
;
Shukla, Nikhil A.
;
Durm, Greg
...
Journal of Thoracic Oncology. , 2024
Link:
https://doi.org/10.1016/..
?
2
A phase 2 trial of chemotherapy plus pembrolizumab in patie..:
Salous, Tareq
;
Shukla, Nikhil A.
;
Althouse, Sandra K.
...
Cancer. 129 (2022) 2 - p. 264-271 , 2022
Link:
https://doi.org/10.1002/..
?
3
Association of Immune-Related Adverse Events and Efficacy O..:
Shukla, Nikhil Atul
;
Althouse, Sandra
;
Meyer, Zachary
..
Clinical Lung Cancer. 22 (2021) 4 - p. 274-281 , 2021
Link:
https://doi.org/10.1016/..
?
4
CX-072 (pacmilimab), a Probody®PD-L1 inhibitor, in advanced..:
Naing, Aung
;
Thistlethwaite, Fiona
;
De Vries, Elisabeth G.E.
...
Journal for ImmunoTherapy of Cancer. 9 (2021) 7 - p. e002447 , 2021
Link:
https://doi.org/10.1136/..
?
5
A multi-center phase II trial evaluating the efficacy of pa..:
Swiecicki, Paul L.
;
Durm, Greg
;
Bellile, Emily
...
Investigational New Drugs. 38 (2020) 5 - p. 1550-1558 , 2020
Link:
https://doi.org/10.1007/..
?
6
A phase 2 trial of consolidation pembrolizumab following co..:
Durm, Greg A.
;
Jabbour, Salma K.
;
Althouse, Sandra K.
...
Cancer. 126 (2020) 19 - p. 4353-4361 , 2020
Link:
https://doi.org/10.1002/..
?
7
Prognostic Variables Associated With Improved Outcomes in P..:
Anouti, Bilal
;
Althouse, Sandra
;
Durm, Greg
.
Clinical Lung Cancer. 21 (2020) 3 - p. 288-293 , 2020
Link:
https://doi.org/10.1016/..
?
8
TMPRSS2-ERG Fusion in an Uncommon Presentation of Prostate ..:
Adra, Nabil
;
Cheng, Liang
;
Hanna, Nasser H.
.
Clinical Genitourinary Cancer. 15 (2017) 3 - p. e489-e491 , 2017
Link:
https://doi.org/10.1016/..
?
9
CX-072 (pacmilimab), a Probody (R) PD-L1 inhibitor, in adva..:
Naing, Aung
;
Thistlethwaite, Fiona
;
De Vries, Elisabeth G. E
...
https://research.rug.nl/en/publications/a4892ae6-f79b-4b98-b444-c3884a663cb4. , 2021
Link:
https://hdl.handle.net/1..
?
10
CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advance..:
Naing, Aung
;
Thistlethwaite, Fiona
;
Vries, Elisabeth G.E, de
...
Reproducció del document publicat a: https://doi.org/10.1136/jitc-2021-002447. , 2021
Link:
http://hdl.handle.net/24..
?
11
A multi-center phase II trial evaluating the efficacy of pa..:
Swiecicki, Paul L
;
Durm, Greg
;
Bellile, Emily
...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9487892/. , 2020
Link:
http://www.ncbi.nlm.nih...
?
12
CX-072 (pacmilimab), a Probody® PD-L1 inhibitor, in advance..:
Hendrik-Tobias Arkenau
;
Marta Gil-Martin
;
Fiona Thistlethwaite
...
https://jitc.bmj.com/content/9/7/e002447.full. , 2021
Link:
https://doi.org/10.1136/..
1-12
